Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study has one working extract — 505(b)(2) literature-to-product bridge table — after a CMO 483 that maps to the NDA CMC module. If 505(b)(2) literature-to-product bridge table cannot support to drop a secondary, the only defensible Pharma & Life Sciences output is hold.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after a CMO 483 that maps to the NDA CMC module. 3. A CMO 483 that maps to the NDA CMC module never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to drop a secondary. 4. Two facts in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). The follow-on FDA Response and Labeling action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for RWE evidence-strategy director - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Missing page in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module, if any - Regulatory or exam hook FDA Response and Labeling would cite